Novavax
NVAX
259 hedge funds and large institutions have $961M invested in Novavax in 2026 Q1 according to their latest regulatory filings, with 56 funds opening new positions, 73 increasing their positions, 72 reducing their positions, and 26 closing their positions.
115% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 26
21% more capital invested
Capital invested by funds: $792M → $961M (+$169M)
10% more funds holding
Funds holding: 235 → 259 (+24)
1% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 72
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.05% less ownership
Funds ownership: 71.65% → 71.6% (-0.05%)
19% less call options, than puts
Call options by funds: $42.6M | Put options by funds: $52.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Coatue Management
New York
|
+$34.8M |
| 2 |
D.E. Shaw & Co
New York
|
+$15.6M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$13.6M |
| 4 |
JFG
Jefferies Financial Group
New York
|
+$6.1M |
| 5 |
EP
Edgestream Partners
Princeton,
New Jersey
|
+$4.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$28.5M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$15M |
| 3 |
SG Americas Securities
New York
|
-$7.57M |
| 4 |
HF
HRT Financial
New York
|
-$7.56M |
| 5 |
Millennium Management
New York
|
-$5.6M |
NVAX Hedge Fund Activity: Q1 2026 in Review
259 of the 8,208 institutional investors tracked by Wall St. Rank reported a position in Novavax (NVAX) for Q1 2026, worth a combined $961M — up 21% from $792M a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new NVAX positions and 26 closed out — a net gain of 30 holders — while 73 added to existing stakes and 72 trimmed.
The largest buyer was Coatue Management, opening a new position worth an estimated $34.8M. The largest seller was Morgan Stanley, cutting an estimated $28.5M.
- 259 institutional investors held Novavax (NVAX) as of Q1 2026, up from 235 in Q4 2025.
- Funds reported $961M of Novavax stock for Q1 2026, up 21% quarter-over-quarter.
- 56 funds opened new Novavax positions in Q1 2026 and 26 closed out, a net change of +30 holders.
- The largest Novavax buyer in Q1 2026 was Coatue Management, an estimated $34.8M added.
- The largest Novavax seller in Q1 2026 was Morgan Stanley, an estimated $28.5M sold.
Based on aggregated 13F filings for Q1 2026.